Xilio Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Xilio Therapeutics, Inc. (XLO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-12
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$1.45M, a 225.41% decline year-over-year.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.54M.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $928.00K.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $3.31M.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$979.00K.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.54M, a 981.71% decline from fiscal 2023.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $175.00K, a 88.96% decline from fiscal 2022.
- Xilio Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.58M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.99M 10-Q · filed 2026-08-12 | -$2.06M derived: sum of 3 quarters · filed 2026-08-12 | $1.25M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$1.54M 10-Q · filed 2026-05-12 | -$608.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.70M derived: sum of 3 quarters · filed 2026-05-12 | $3.86M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $928.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.24M derived: sum of 2 quarters · filed 2026-03-23 | $5.40M derived: sum of 3 quarters · filed 2026-08-12 | -$979.00K 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.47M derived: sum of 2 quarters · filed 2026-08-12 | -$1.91M 10-Q · filed 2025-11-13 | -$1.99M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.22M 10-Q · filed 2026-08-12 | -$5.30M derived: sum of 3 quarters · filed 2026-08-12 | -$5.51M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$6.38M 10-Q · filed 2026-05-12 | -$6.10M 10-Q · filed 2025-05-08 | -$6.46M derived: sum of 2 quarters · filed 2026-05-12 | -$6.67M derived: sum of 3 quarters · filed 2026-05-12 | -$5.42M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$296.00K derived: sum of 2 quarters · filed 2026-03-23 | $952.00K derived: sum of 3 quarters · filed 2026-03-23 | -$1.54M 10-K · filed 2026-03-23 | -$496.00K 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.04M derived: sum of 2 quarters · filed 2025-11-13 | -$1.46M 10-Q · filed 2025-11-13 | -$684.00K 10-Q · filed 2024-11-07 | -$355.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.25M 10-Q · filed 2025-08-14 | -$740.00K 10-Q · filed 2024-08-08 | -$144.00K derived: sum of 3 quarters · filed 2025-08-14 | $2.13M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$2.50M 10-Q · filed 2025-05-08 | -$1.39M derived: sum of 2 quarters · filed 2025-05-08 | $884.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.55M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.38M derived: sum of 2 quarters · filed 2025-03-11 | $4.04M derived: sum of 3 quarters · filed 2025-03-11 | $175.00K 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.94M derived: sum of 2 quarters · filed 2024-11-07 | -$928.00K 10-Q · filed 2024-11-07 | $541.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.20M 10-Q · filed 2024-08-08 | -$1.74M derived: sum of 3 quarters · filed 2024-08-08 | -$4.82M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$3.87M 10-Q · filed 2024-05-14 | -$2.40M derived: sum of 2 quarters · filed 2024-05-14 | -$5.49M derived: sum of 3 quarters · filed 2024-05-14 | -$856.00K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.62M derived: sum of 2 quarters · filed 2024-04-01 | $3.01M derived: sum of 3 quarters · filed 2024-04-01 | $1.58M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.54M derived: sum of 2 quarters · filed 2023-11-09 | $116.00K 10-Q · filed 2023-11-09 | $958.00K derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.20M 10-Q · filed 2023-08-14 | $4.05M derived: sum of 3 quarters · filed 2023-08-14 | $3.75M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$1.43M 10-Q · filed 2023-05-09 | -$585.00K derived: sum of 2 quarters · filed 2023-05-09 | -$885.00K derived: sum of 3 quarters · filed 2023-05-09 | -$2.42M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $842.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $542.00K derived: sum of 2 quarters · filed 2023-03-02 | -$990.00K derived: sum of 3 quarters · filed 2023-03-02 | -$5.62M 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.83M derived: sum of 2 quarters · filed 2022-11-09 | -$6.46M 10-Q · filed 2022-11-09 | -$692.00K derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$6.16M 10-Q · filed 2022-08-09 | -$392.00K derived: sum of 3 quarters · filed 2022-08-09 | |||||
| 2021-03-31 | -$4.63M 10-Q · filed 2022-05-12 | $1.14M derived: sum of 2 quarters · filed 2022-05-12 | ||||||
| 2020-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $11.51M 10-K · filed 2022-03-01 | ||||||
| 2020-09-30 | $5.74M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |